Leerink Partners Maintains its Outperform Rating and Increases its Price Target for UnitedHealth Group Incorporated (UNH) from $300 to $402

UnitedHealth Group Incorporated (NYSE:UNH) is one of the 11 Most Profitable Blue Chip Stocks to Buy Right Now.

Leerink Partners Maintains its Outperform Rating and Increases its Price Target for UnitedHealth Group Incorporated (UNH) from $300 to $402

Leerink Partners maintained its Outperform rating and increased its price target for UnitedHealth Group Incorporated (NYSE:UNH) from $300 to $402 on September 24, 2025, citing a strong upside case fueled by an earlier-than-expected turnaround in Optum operations. The company reported a strong $16 EPS floor for the current year, reduced risks from Medicare Advantage Star ratings, and possible earnings of $25 per share compared to a consensus of $21.

On the same day, the UnitedHealth Group Store, a digital health and wellness platform that offers up to 15% off programs ranging from orthopedic management to weight reduction, was launched by UnitedHealth Group Incorporated (NYSE:UNH). It is currently accessible to 6 million members and is expected to expand to 18 million by the end of the year. These actions demonstrate UnitedHealth Group (NYSE:UNH)’s strategy of combining strong financial results with innovative, member-focused digital offerings.

Through UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, UnitedHealth Group Incorporated (NYSE:UNH) provides insurance, care services, and technology-enabled healthcare solutions both domestically and internationally. It is one of Most Profitable Stocks.

While we acknowledge the potential of UNH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UNH and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.